WuXi Biologics has been named to the CDP Supplier Engagement Assessment A List for the second consecutive year, recognizing its leadership in climate-related supplier engagement and strong sustainability performance. The company also earned spots on CDP's Climate Change and Water Security A Lists, reflecting its commitment to environmental transparency and supply chain climate action. WuXi Biologics pursues Science Based Targets initiative-approved emissions reduction goals, aiming for net-zero emissions across its value chain by 2050. This recognition supports its position as a global leader in sustainable biologics development and manufacturing.
DBV Technologies has begun screening the first participant in its phase 2 THRIVE clinical trial to test the VIASKIN Peanut patch on infants aged 6 to 12 months with peanut allergies. The study aims to evaluate the patch's safety and effectiveness in ...
Robbins LLP is investigating Beta Bionics, Inc.'s officers and directors for potential violations of securities laws and breaches of fiduciary duties following the company's announcement of weaker-than-expected patient growth. Beta Bionics reported a...
Robbins LLP is investigating whether officers and directors of Simulation Plus, Inc. violated securities laws and breached fiduciary duties following significant stock price drops in 2025. The company faced a 24% stock decline after lowering revenue ...
Strategy Inc. sold 32 BTC for $2.5 million to fund preferred stock dividends, spotlighting a growing challenge for bitcoin treasury companies: managing liquidity without selling core bitcoin holdings. This small sale, from a large BTC reserve, raises...
Surge Energy has increased its 2026 production guidance to 24,000 boe/d and raised capital spending to C$175 million, targeting C$335 million in adjusted funds flow (AFF) at US$80 WTI. The company currently offers a 16.9% free cash flow yield and pla...
